CCR2 and rheumatoid arthritis: Approved in 2015 for the treatment of liposarcoma and leiomyosarcoma, the chemotherapeutic anti-CCR2 agent trabectedin can selectively deplete monocytes and macrophages in blood and tissues (74) and could be worth testing in RA despite its potentially serious off-target effects, given that other antitumor drugs (such as methotrexate) have been proven to be useful in chronic autoimmune inflammations such as RA.